✦ LIBER ✦

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Scribed by Katsuyuki Hotta; Yoshiro Fujiwara; Keitaro Matsuo; Takeshi Suzuki; Katsuyuki Kiura; Masahiro Tabata; Nagio Takigawa; Hiroshi Ueoka; Mitsune Tanimoto

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 264 KB
Volume: 109
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22478

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recent improvement in the survival of pa

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Alessandra Bearz; Diego Serraino; Lucia Fratino; Massimiliano Berretta; Umberto 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 3 views

A recent article by Hotta and colleagues 1 reports that survival of patients with nonsmall cell lung cancer (NSCLC) improved slowly over time from 1982 to 2002. Authors pooled together 121 phase 3 trials (42,768 patients overall),

Author reply to recent improvement in th

Author reply to recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Katsuyuki Hotta; Yoshiro Fujiwara; Keitaro Matsuo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB

Phase 1 trial of everolimus and gefitini

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer

✍ Daniel T. Milton; Gregory J. Riely; Christopher G. Azzoli; Jorge E. Gomez; Rober 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

## Abstract ## BACKGROUND. Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dos

Prognostic influence of metformin as fir

Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes

✍ Ben-Xu Tan; Wen-Xiu Yao; Jun Ge; Xing-Chen Peng; Xiao-Bo Du; Ru Zhang; Bin Yao; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB 👁 2 views

Phase II study of pemetrexed in combinat

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

✍ Ralph G. Zinner; Frank V. Fossella; Gregory W. Gladish; Bonnie S. Glisson; Georg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

A Phase II trial of gemcitabine and doce

A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma

✍ Irina E. Popa; Kathleen Stewart; Frederick P. Smith; Naiyer A. Rizvi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Abstract ## BACKGROUND The goals of the current study were to determine the safety and efficacy of a nonplatinum‐containing doublet, gemcitabine and docetaxel, in the treatment of patients with chemotherapy‐naive nonsmall cell lung carcinoma (NSCLC). ## METHODS Thirty‐two patients with advanc